Regeneron Pharmaceuticals Inc. (REGN)

387.25
NASDAQ : Health Technology
Prev Close 387.25
Day Low/High 0.00 / 0.00
52 Wk Low/High 281.89 / 477.00
Avg Volume 729.80K
Exchange NASDAQ
Shares Outstanding 106.14M
Market Cap 41.46B
EPS 11.30
P/E Ratio 27.80
Div & Yield N.A. (N.A)

Latest News

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab)Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab)Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

Last month, FDA also approved Praluent label update for some patients currently requiring LDL apheresis therapy

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Fri. 8/31/18)

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Fri. 8/31/18)

Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

Teva And Regeneron Announce Positive Topline Phase 3 Fasinumab Results In Patients With Chronic Pain From Osteoarthritis Of The Knee Or Hip

Teva And Regeneron Announce Positive Topline Phase 3 Fasinumab Results In Patients With Chronic Pain From Osteoarthritis Of The Knee Or Hip

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer

bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc.

Regeneron Soars After My 'Go Long' Recommendation: What Now?

Regeneron Soars After My 'Go Long' Recommendation: What Now?

An updated strategy for the high-flying REGN.

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Thursday 7/26/18)

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Thursday 7/26/18)

Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMD, ARII, GLW, NEP, REGN, UHAL Downgrades: ASTE, GEC, SINO, SXT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Regeneron Pharmaceuticals Takes Over #154 Spot From Kimberly-Clark Corp.

Regeneron Pharmaceuticals Takes Over #154 Spot From Kimberly-Clark Corp.

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Regeneron Pharmaceuticals, Inc. has taken over the #154 spot from Kimberly-Clark Corp.

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Tuesday 6/26/18)

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Tuesday 6/26/18)

Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer takes a look at Kraft Heinz, VF Corp, Cimarex Energy, STORE Capital, Wheaton Precious Metals, Bluebird Bio, First Commonwealth Financial Corp.

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Jim Cramer says many stocks already reflect the worst-case scenarios, and that means he sees a lot of upside potential.

Regeneron Is Leading the Way for Biotech

Regeneron Is Leading the Way for Biotech

Recent action tells us REGN's momentum is super strong.

Chart of the Day: Regeneron

Wednesday’s action tells us REGN’s momentum is super strong.

Regeneron Pharmaceuticals Becomes #47 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

Regeneron Pharmaceuticals Becomes #47 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Regeneron And Zoetis Announce Collaboration To Research Antibody Therapies For Use In Animal Health

Regeneron And Zoetis Announce Collaboration To Research Antibody Therapies For Use In Animal Health

Collaboration will also generate preclinical data to inform Regeneron's development of human medicines

Nasdaq's on Fire: Cramer's 'Mad Money' Recap (Monday 6/4/18)

Nasdaq's on Fire: Cramer's 'Mad Money' Recap (Monday 6/4/18)

Jim Cramer talks about the stocks and sectors behind the resurgence fueling the Nasdaq's gains.

TheStreet Quant Rating: B- (Buy)